Biotechnology
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence , today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a ...
2026-05-12 20:30
4806
DNA 'barcodes' help NUS researchers pinpoint gold nanoparticles that can strike cancer at its power source
A new high-throughput platform screens dozens of nanoparticle designs in living systems to identify those that reach tumour mitochondria, enabling more precise and effective cancer therapies SINGAPORE, May 12, 2026 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have de...
2026-05-12 14:59
6678
Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
BOSTON and HANGZHOU, China, May 11, 2026 /PRNewswire/ -- Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the peer-reviewed journal Cancer Discovery. R...
2026-05-11 21:00
5467
Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
NANJING, China, May 11, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) successfully held its R&D Symposium in Shanghai. Under the theme "Leads Innovation, Future Forward", the event comprehensively presented the Company's strategic elevation from "mul...
2026-05-11 19:00
5582
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
NEWARK, Del., May 9, 2026 /PRNewswire/ -- ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrative process to a streamlined, purchase-based authorization model. This policy shift addresses the i...
2026-05-10 01:30
7010
World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application
SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance...
2026-05-09 08:00
7024
TOOTOO Self-Develops Ultra-Olaflur, Achieving a New Breakthrough in Super Cavity Protection for Children's Toothpaste
* Acid erosion resistance increased by 5 times, remineralization effect 1.7 times higher than previous generation Olaflur HANGZHOU, China, May 8, 2026 /PRNewswire/ -- Recently, Chinese children's age-specific wash and care brand TOOTOO (a brand under Hangzhou Daoyu Xingqing Biotechnology Co., L...
2026-05-08 18:21
4531
BioQ Debuts at in‑cosmetics Global, Showcasing China's Advancing Strength in Ingredient Innovation
PARIS, May 8, 2026 /PRNewswire/ -- BioQ, the biotechnology affiliate of Chinese skincare brand GUYU, made its first appearance as a raw-material supplier at in-cosmetics Global, held April 14–16, 2026, in Paris. Widely regarded as the most prestigious stage for cosmetic ingredients, the event adm...
2026-05-08 17:34
3946
Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to 'RZ-001' for Hepatocellular Carcinoma
RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, with trans-splicing ribozyme-based RNA editing platform SEOUL, South Korea, May 8, 2026 /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene ther...
2026-05-08 16:17
4946
Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87
HANGZHOU, China, May 7, 2026 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that the Center for Drug Evaluation of China's National Medical P...
2026-05-08 08:30
4719
Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation
CAMBRIDGE, Mass., May 6, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao as Chief Scientific Officer (CSO). Dr. Xiao will be...
2026-05-07 11:29
5121
(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity SYDNEY, May 6, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical c...
2026-05-06 19:00
4566
Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced the completion of p...
2026-05-06 12:00
5124
Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year
* Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution * Recognition highlights proactive alignment with evolving expectations from global stakeholders INCHEON, South Korea, May 5, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a l...
2026-05-05 19:00
6071
Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy
* Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit. * No dose-limiting toxicities (DLTs) or drug-related serious adve...
2026-05-01 14:30
11229
Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage ...
2026-04-30 14:30
7031
New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen's Team
SHANGHAI, April 30, 2026 /PRNewswire/ -- A seminal research paper titled "A New Classification System for Malocclusions with Facial Convexity"has been officially published in the 2026 Volume 1 issue of the Journal of Aligner Orthodontics (JAO). This article, authored by Professor Gang Shen and hi...
2026-04-30 13:33
5737
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
SHANGHAI, April 30, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be ...
2026-04-30 12:26
6211
Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million
Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biotechnology company focused on revolutionizing in vivo CAR-T therapies, announc...
2026-04-29 20:15
3786
ESG | HitGen Releases 2025 Sustainability Report
CHENGDU, China, April 29, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) released its 2025 Sustainability Report on April 29, 2026. This report is the second sustainability report of HitGen, aiming to present the Company's philosophies and polic...
2026-04-29 19:00
4707
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 281 media titles]
2026-09-23 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13706
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12422
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11441
